Product/Composition:- | Norfloxacin tablerts |
---|---|
Strength:- | 400 mg, 200 mg |
Form:- | Tablet |
Reference Brands:- | Noroxin(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Norfloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and bacterial growth. It effectively treats urinary tract and bacterial infections. Benefits include rapid bacterial eradication, broad-spectrum activity, oral convenience, and safety when used appropriately. It provides reliable, effective treatment for uncomplicated bacterial infections.
Norfloxacin tablets are approved in the EU and US for urinary tract infections. In the EU, brands and generics are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic versions are widely available. Both regions require detailed dossiers including clinical trial results, quality assurance, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for norfloxacin tablets, ensuring adherence to European and US standards for safe, effective antimicrobial therapy in managing bacterial infections.